Acquisition by Stryker Cerus Endovascular was acquired by Stryker in May 2023, indicating access to a larger distribution network, capital, and cross selling opportunities for neurovascular devices and related delivery systems.

FDA clearance momentum Recent FDA 510(k) clearance for 027 microcatheters signals ongoing regulatory progress and product expansion, creating openings for hospital and vendor partnerships to adopt Cerus-endorsed neurointerventional solutions.

Early-stage revenue With a current revenue range of zero to one million and a small employee base, there is a clear path for channel partners to assist in market expansion, rev share models, and accelerated sales through Stryker’s global footprint.

Strategic market focus Specialization in interventional neuroradiology devices for intracranial aneurysms positions Cerus for collaboration with major neurovascular centers and distributors focusing on high-need neurovascular treatment portfolios.

Clinical study momentum Past initiation of the CERUS study and ongoing clinical activity offer opportunities for research collaborations, sponsored trials, and bundled offerings with caregivers and teaching hospitals seeking innovative endovascular solutions.